-
1.发明公开公开(公告)号：US20230248667A1
公开(公告)日：2023-08-10
申请号：US18105795
申请日：2023-02-03
申请人： Aurobindo Pharma Ltd
发明人： Soumyajit Behera , Satheesh Kumar Gajjala , Nilesh Bhandari , Nagaprasad Vishnubhotla , Sivakumaran Meenakshisunderam
IPC分类号： A61K31/137 , A61K31/495 , A61K9/28
CPC分类号： A61K31/137 , A61K31/495 , A61K9/2893 , A61K9/2866 , A61K9/282
摘要： This invention relates to dosage forms comprising pseudoephedrine or a salt thereof, for extended-release up to 24 hours, and process of making such dosage forms. This invention provides a non-osmotic extended-release dosage form comprising pseudoephedrine hydrochloride which can be administered to patients who need and/or desire a decongestant medication up to 24 hours. This invention also relates to dosage forms comprising pseudoephedrine or a salt thereof and cetirizine or levocetirizine or its salts thereof for extended-release up to 24 hours, and process of making such dosage forms.
-
2.发明申请公开(公告)号：US20210177822A1
公开(公告)日：2021-06-17
申请号：US17119250
申请日：2020-12-11
IPC分类号： A61K31/4468 , A61K9/48 , A61K9/00
摘要： The present invention relates to prepare pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof, processes for manufacturing said pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof. Also pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
-
公开(公告)号：US20180008547A1
公开(公告)日：2018-01-11
申请号：US15548063
申请日：2016-02-01
申请人： Shridhar INAGANTI , Venugopala CHOKKASANDRA JAYARAMA REDDY , Jayant KARAJGI , Sivakumaran MEENAKSHISUNDERAM , AUROBINDO PHARMA LTD
发明人： Shridhar Inaganti , Venugopala Chokkasandra Jayarama Reddy , Jayant Karajgi , Sivakumaran Meenakshisunderam
CPC分类号： A61K9/4808 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K38/10
摘要： The present invention relates to stable oral composition comprising linaclotide or its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates, process of preparation thereof and methods of using the same.
-
4.发明授权公开(公告)号：US11648242B2
公开(公告)日：2023-05-16
申请号：US17119250
申请日：2020-12-11
IPC分类号： A61K31/4468 , A61K9/48 , A61K9/00
CPC分类号： A61K31/4468 , A61K9/0053 , A61K9/485 , A61K9/4833 , A61K9/4858 , A61K9/4866
摘要： The present invention relates to prepare pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof, processes for manufacturing said pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof. Also pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
-
公开(公告)号：US20200253955A1
公开(公告)日：2020-08-13
申请号：US16462856
申请日：2017-11-22
申请人： Aurobindo Pharma Ltd
发明人： Rama Shankar , Nimesh Chandra Misra , Siva Rama Kasibabu Velegula , Suresh Chapala , Sivakumaran Meenakshisunderam
IPC分类号： A61K31/485
摘要： The present invention relates to solid dispersion of Naloxegol oxalate. Further, the present invention relates to an improved process for Naloxegol oxalate and intermediates thereof.
-
公开(公告)号：US11969413B2
公开(公告)日：2024-04-30
申请号：US17510797
申请日：2021-10-26
申请人： Aurobindo Pharma Ltd
发明人： Saravanan Kannusamy , Prabhakaran Chakkirala , Nagaprasad Vishnubhotla , Sivakumaran Meenakshisunderam
IPC分类号： A61K9/20 , A61K31/4375
CPC分类号： A61K31/4375 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K9/2077
摘要： This present invention relates to pharmaceutical composition comprising Deutetrabenazine. The invention also relates to the methods of preparation of the composition having improved stability and dissolution profile and used for the treatment of chorea associated with Huntington disease and tardive dyskinesia.
-
公开(公告)号：US20160108058A1
公开(公告)日：2016-04-21
申请号：US14888702
申请日：2014-02-07
发明人： Shankar Reddy Budidet , Nageshwar Dussa , Gowrisankar Rao Kaki , Srinivasa Rao Yatcherla , Jagan Mohan Reddy Sanapureddy , Subba Reddy Danda , Srinivasachary Katuroju , Sivakumaran Meenakshisunderam
IPC分类号： C07D498/14 , C07C215/08 , C07C213/08 , C07C59/255
CPC分类号： C07D498/14 , C07C59/255 , C07C213/02 , C07C213/08 , C07C213/10 , C07C215/08
摘要： The present invention provides (R)-3-Amino-1-butanol (D)-tartarate (IIb); process for its preparation and its conversion to Dolutegravir. The present invention also provides an improved process for the preparation of Dolutegravir (I) or pharmaceutically acceptable salts wherein compound (XVI) is reacted with an optically active acid addition salt of (R)-3-amino-1-butanol (IIa).
摘要翻译： 本发明提供（R）-3-氨基-1-丁醇（D） - 三硬脂酸酯（IIb）; 其制备过程及其转化为Dolutegravir。 本发明还提供了制备Dolutegravir（I）或其药学上可接受的盐的改进方法，其中化合物（XVI）与（R）-3-氨基-1-丁醇（IIa）的旋光酸加成盐反应。
-
公开(公告)号：US20240358695A1
公开(公告)日：2024-10-31
申请号：US18643177
申请日：2024-04-23
申请人： Aurobindo Pharma Ltd
发明人： Sreekanth Manikonda , Avinash Reddy Manda , Siva Kumar Reddy Chamala , Nagaprasad Vishnubhotla , Sivakumaran Meenakshisunderam
IPC分类号： A61K31/4545 , A61K9/20
CPC分类号： A61K31/4545 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2095
摘要： The present invention relates to rapidly disintegrating pharmaceutical composition comprising Rimegepant or pharmaceutically acceptable salt thereof, and processes for manufacture thereof.
-
公开(公告)号：US11161821B2
公开(公告)日：2021-11-02
申请号：US15733804
申请日：2019-05-16
发明人： Moturu Venkata Ramakrishna Murthy , Tiwari Shashi Kant , Nadakudity Sailendra Kumar , Samala Bhanuchander , Rajesh Chennuri , Srinivasa Chary Katuroju , Sivakumaran Meenakshisunderam
IPC分类号： C07D231/48
摘要： The present invention relates to an improved process for the purification of Eltrombopag olamine of compound of formula (2). The present invention also relates to an improved process for the preparation of Eltrombopag olamine intermediates and further conversion to Eltrombopag olamine of a compound of formula (2).
-
公开(公告)号：US09573965B2
公开(公告)日：2017-02-21
申请号：US14888702
申请日：2014-02-07
申请人： Aurobindo Pharma Ltd
发明人： Shankar Reddy Budidet , Nageshwar Dussa , Gowrisankar Rao Kaki , Srinivasa Rao Yatcherla , Jagan Mohan Reddy Sanapureddy , Subba Reddy Danda , Srinivasachary Katuroju , Sivakumaran Meenakshisunderam
IPC分类号： C07D498/14 , C07C213/08 , C07C215/08 , C07C213/02 , C07C213/10 , C07C59/255
CPC分类号： C07D498/14 , C07C59/255 , C07C213/02 , C07C213/08 , C07C213/10 , C07C215/08
摘要： The present invention provides (R)-3-Amino-1-butanol (D)-tartarate (IIb); process for its preparation and its conversion to Dolutegravir. The present invention also provides an improved process for the preparation of Dolutegravir (I) or pharmaceutically acceptable salts wherein compound (XVI) is reacted with an optically active acid addition salt of (R)-3-amino-1-butanol (IIa).
摘要翻译： 本发明提供（R）-3-氨基-1-丁醇（D） - 三硬脂酸酯（IIb）; 其制备过程及其转化为Dolutegravir。 本发明还提供了制备Dolutegravir（I）或其药学上可接受的盐的改进方法，其中化合物（XVI）与（R）-3-氨基-1-丁醇（IIa）的旋光酸加成盐反应。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.013 秒)
